From the report:-
2 Health Plans are now paying under a pilot program of coverage, prior to us obtaining commercial coverage.
The way I read this is that we now have de facto 2 private payors on board. The pilot program is clearly not to confirm the efficacy of the product (that has already been established). I assume it is to make sure the administrative processes are in place to manage a high volume of claims that will come with commercial coverage. So if the is the case it would not be unreasonable to expect that other payors will fall into line. insurance being very competitive industry.
Also from the conference call (thanks @Bloky ) it was stated the NCCN panel assessing the inclusion would be aware that the 'tape measure basically doesn't work'. Therefore TM is not an alternative diagnostic tool. Now nothing is guaranteed but it would seem an odd outcome if BIS L dex was not included in the NCCN as the standard of care as we would be left with the status quo, ie with many practitioners still using the TM. So you can understand why they have 'a high level of confidence) they will be included.
I am encouraged by how this is progressing.
imo only and dyor.
- Forums
- ASX - By Stock
- IPD
- Ann: Appendix 4C & Quarterly Activities Report - Sep-22 Qtr
Ann: Appendix 4C & Quarterly Activities Report - Sep-22 Qtr, page-15
Featured News
Add IPD (ASX) to my watchlist
|
|||||
Last
4.8¢ |
Change
0.001(2.13%) |
Mkt cap ! $97.10M |
Open | High | Low | Value | Volume |
4.6¢ | 4.8¢ | 4.6¢ | $72.92K | 1.564M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 353687 | 4.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 253687 | 0.046 |
2 | 350000 | 0.045 |
2 | 242899 | 0.044 |
3 | 500000 | 0.043 |
3 | 341830 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 100000 | 1 |
0.050 | 34000 | 2 |
0.051 | 106000 | 2 |
0.052 | 192812 | 1 |
0.053 | 300000 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |